Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-01
2011-03-01
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S154000
Reexamination Certificate
active
07897591
ABSTRACT:
The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestinal operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor.
REFERENCES:
patent: 3856953 (1974-12-01), Saltzman
patent: 99/61413 (1999-12-01), None
patent: WO9961413 (1999-12-01), None
patent: 2004/091603 (2004-10-01), None
patent: 2005/046669 (2005-05-01), None
Adams et al. (Treatment of non-alcoholic fatty liver disease, Postgrad Med J. May 2006; 82(967): 315-322).
Wielockx, Ben et al., Nature Medicine, “Inhibition of matrix metalloporteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy,” 7(11):1202-1208 (2001).
Achord, J.L., The American Journal of Gastroenterology, 88(11):1822-1828 (1993). “Review of Alcoholic Hepatitis and Its Treatment.”
Reye, et al., Lancet, 2:749 (1963). “Encephalopathy and Fatty Degeneration of the Viscera.”
Schubert, et al., Popper, H. and Schaffner, F. (eds.): Progress in Liver Diseases, Chapter 28, 4th Edition, New York, Grune and Stratton, Inc., pp. 489-510 (1972). “Encephalopathy and Fatty Liver (Reye's Syndrome).”
Moses Marsha A.
Puder Mark
Betton Timothy E
Children's Medical Center Corporation
Nixon & Peabody LLP
Padmanabhan Sreeni
LandOfFree
Method of treating fatty liver disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating fatty liver disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating fatty liver disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2623061